Search

Your search keyword '"Finel, H"' showing total 8 results
Start Over Author "Finel, H" Journal hematological oncology
8 results on '"Finel, H"'

1. Efficacy and toxicity of CAR T‐cell therapy in patients with primary and secondary central nervous system lymphoma—an analysis of the EBMT Lymphoma WP and the GoCART coalition.

Author

Laube, A., Fuhrmann, S., Peczynski, C., Boumendil, A., Michel, E., Finel, H., Galimard, J., Beauvais, D., Daskalakis, M., Novak, U., Kröger, N., Stelljes, M., von Tresckow, B., Wulf, G. G., Dreger, P., Sureda, A., Schmitz, N., and Glaß, B.

Subjects
CENTRAL nervous system, DIFFUSE large B-cell lymphomas, LYMPHOMAS, T cells
Abstract

B Conclusion: b With a 51% OS-rate at 12 months CART seem to be a very effective therapeutic option in heavily pre-treated r/r PCNSL or SCNSL, particularly for pts being refractory to prior therapy. Pts with involvement of the CNS were excluded from most CART trials; however, anecdotal reports suggest that CART might be an effective treatment option for such pts. B Introduction: b The prognosis of patients (pts) with diffuse large B-cell lymphoma (DLBCL) and involvement of the central nervous system (CNS) remains dismal. [Extracted from the article]

Published
2023
Full Text
View/download PDF

2. ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION FOR PERIPHERAL T‐CELL LYMPHOMA: COMPARABLE OUTCOMES OF HAPLO‐IDENTICAL VS. MATCHED DONORS. A CIBMTR & EBMT ANALYSIS

Author

Dreger, P., primary, Ngoya, M., additional, Litovich, C., additional, Finel, H., additional, Herrera, A. F, additional, Sauter, C., additional, Kharfan‐Dabaja, M., additional, Sureda, A., additional, Blaise, D., additional, Castagna, L., additional, Corradini, P., additional, Pastano, R., additional, Arat, M., additional, Boumendil, A., additional, Dietrich, S., additional, Schmitz, N., additional, Glass, B., additional, Montoto, S., additional, and Hamadani, M., additional

Published
2021
Full Text
View/download PDF

3. HOW TO SELECT DONOR, STEM CELL SOURCE, AND CONDITIONING REGIMEN FOR HAPLOIDENTICAL TRANSPLANTS WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE FOR LYMPHOMA: A REPORT OF THE EBMT LWP

Author

Bazarbachi, A., primary, Boumendil, A., additional, Finel, H., additional, Castagna, L., additional, Dominietto, A., additional, Blaise, D., additional, Diez-Martin, J., additional, Tischer, J., additional, Gülbas, Z., additional, Labussière Wallet, H., additional, Lopez Corral, L., additional, Mohty, M., additional, Koc, Y., additional, Yakoub-Agha, I., additional, Schmid, C., additional, el Cheikh, J., additional, Arat, M., additional, Forcade, E., additional, Dreger, P., additional, Rocha, V., additional, Gutiérrez García, G., additional, Chalandon, Y., additional, Ferra, C., additional, Orvain, C., additional, Robinson, S., additional, Montoto, S., additional, and Sureda, A., additional

Published
2019
Full Text
View/download PDF

4. THE EFFICACY OF IBRUTINIB IN PATIENTS WITH RELAPSED MANTLE CELL LYMPHOMA AFTER FIRST LINE INTENSIVE CHEMO-IMMUNOTHERAPY AND ASCT - A RETROSPECTIVE STUDY FROM THE LWP-EBMT

Author

Burney, C.N., primary, Robinson, S., additional, Boumendil, A., additional, Finel, H., additional, Khvedelidze, I., additional, Hunter, H., additional, Poire, X., additional, Lioure, B., additional, Peggs, K., additional, Foa, R., additional, Pillai, S., additional, van Meerten, T., additional, Bargay Lleonart, J., additional, Schmid, C., additional, Vergote, V., additional, Ganser, A., additional, Castagna, L., additional, Mufti, G., additional, and Montoto, S., additional

Published
2019
Full Text
View/download PDF

5. DONOR LYMPHOCYTE INFUSIONS INDUCE DURABLE RESPONSES IN PATIENTS WITH FOLLICULAR, MANTLE AND T CELL LYMPHOMAS RELAPSING AFTER AN ALLOSCT. AN EBMT-LWP STUDY

Author

Robinson, S., primary, Boumendil, A., additional, Finel, H., additional, Khvedelidze, I., additional, Kanfer, E., additional, Peggs, K., additional, Fuesrt, S., additional, Ram, R., additional, Marjit, E., additional, Vandenberghe, E., additional, Afanasyev, B., additional, Wulf, G., additional, Maertens, J., additional, Tsolukani, A., additional, Schapp, N., additional, Beelen, D., additional, Chalandon, Y., additional, Gurman, G., additional, Finke, J., additional, Bron, D., additional, Tischer, J., additional, Corradini, P., additional, Caballero, D., additional, Potter, V., additional, Kroger, N., additional, Burney, C., additional, Schmitz, N., additional, Sureda, A., additional, Dreger, P., additional, and Montoto, S., additional

Published
2019
Full Text
View/download PDF

6. ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (ALLO-HSCT) FOR PATIENTS WITH RELAPSED/REFRACTORY SYSTEMIC ANAPLASTIC LARGE CELL LYMPHOMA (R/R SALCL). A RETROSPECTIVE ANALYSIS OF THE LYMPHOMA WORKING PARTY-EBMT.

Author

Domingo Domenech, E., primary, Boumendil, A., additional, Climent, F., additional, Socié, G., additional, Kroschinsky, F., additional, Finel, H., additional, Vandenbergue, E., additional, Nemet, D., additional, Stelljes, M., additional, Bittenbring, J., additional, Montoto, S., additional, Sureda, A., additional, and Dreger, P., additional

Published
2017
Full Text
View/download PDF

7. BRENTUXIMAB VEDOTIN FOR RELAPSED HODGKIN LYMPHOMA AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION: a RETROSPECTIVE STUDY OF THE EBMT LYMPHOMA WORKING PARTY

Author

Bazarbachi, A., primary, Boumendil, A., additional, Finel, H., additional, Mohty, M., additional, Castagna, L., additional, Blaise, D., additional, Peggs, K., additional, Afanasyev, B., additional, Diez-Martin, J., additional, Corradini, P., additional, Socié, G., additional, Robinson, S., additional, Gutiérrez-García, G., additional, Bonifazi, F., additional, Yakoub-Agha, I., additional, Gülbas, Z., additional, Bloor, A., additional, Delage, J., additional, Esquirol, A., additional, Malladi, R., additional, Scheid, C., additional, Ghesquières, H., additional, Montoto, S., additional, Dreger, P., additional, and Sureda, A., additional

Published
2017
Full Text
View/download PDF

8. Autologous hematopoietic cell transplantation (autoHCT) for T‐cell/histiocyte‐rich large B‐cell lymphoma (THRLBCL): An EBMT Lymphoma Working Party study.

Author

Renders, S., Finel, H., Ngoya, M., Boumendil, A., Schaap, N., Ghesquieres, H., Bloor, A., Pérez‐Simón, J. A., Huynh, A., Kobbe, G., Collin, M., Busca, A., Helbig, G., Aljurf, M., Daskalakis, M., Schroers, R., Carpenter, B., Rubio, M. T., Peniket, A., and Sureda, A.

Subjects
HEMATOPOIETIC stem cell transplantation, LYMPHOMAS, DELAYED diagnosis, SEZARY syndrome
Abstract

THRLBCL patients were younger (52 vs. 58 years), predominantly male (76% vs. 59%), had better performance status (ECOG 0: 97% vs. 92%) and less comorbidity (HCT-CI 0: 78% vs. 68%), and had a longer time from diagnosis to transplant (13 vs. 11 months) than DLBCL patients. B Introduction: b THRLBCL is an orphan entity of large B-cell lymphomas (LBCL). Superior outcome of autoHCT for THRLBCL compared to DLBCL may be partly explained by more favorable baseline features of the THRLBCL group in terms of age, and PS. [Extracted from the article]

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results